Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$213M Buy
1,773,100
+652,000
+58% +$75.3M 0.09% 205
2025
Q4
$118M Sell
1,121,100
-604,600
-35% -$56.8M 0.05% 317
2025
Q3
$145M Buy
1,725,700
+874,100
+103% +$72M 0.06% 293
2025
Q2
$67.4M Buy
851,600
+197,600
+30% +$15.7M 0.03% 487
2025
Q1
$58.7M Sell
654,000
-113,400
-15% -$10.6M 0.03% 509
2024
Q4
$76.3M Buy
767,400
+103,500
+16% +$10.7M 0.05% 362
2024
Q3
$75.4M Buy
663,900
+33,600
+5% +$3.99M 0.04% 360
2024
Q2
$78M Sell
630,300
-532,200
-46% -$68.6M 0.05% 348
2024
Q1
$153M Buy
1,162,500
+433,200
+59% +$53.4M 0.1% 191
2023
Q4
$79.5M Buy
729,300
+107,800
+17% +$11.2M 0.06% 300
2023
Q3
$64M Buy
621,500
+18,100
+3% +$1.95M 0.05% 337
2023
Q2
$69.6M Buy
603,400
+275,100
+84% +$31.2M 0.05% 335
2023
Q1
$34.9M Buy
328,300
+41,300
+14% +$4.46M 0.02% 544
2022
Q4
$31.8M Sell
287,000
-216,200
-43% -$22.1M 0.03% 577
2022
Q3
$43.3M Sell
503,200
-470,000
-48% -$42M 0.03% 428
2022
Q2
$88.7M Sell
973,200
-275,500
-22% -$24.4M 0.07% 240
2022
Q1
$102M Sell
1,248,700
-188,100
-13% -$14.8M 0.06% 281
2021
Q4
$110M Buy
1,436,800
+162,000
+13% +$12.9M 0.06% 288
2021
Q3
$95.8M Buy
1,274,800
+837,700
+192% +$63.7M 0.06% 301
2021
Q2
$34M Buy
437,100
+89,478
+26% +$6.66M 0.02% 705
2021
Q1
$25.6M Sell
347,622
-149,340
-30% -$11M 0.02% 820
2020
Q4
$38.8M Sell
496,962
-36,575
-7% -$2.8M 0.02% 673
2020
Q3
$42.2M Buy
533,537
+163,803
+44% +$12.8M 0.03% 519
2020
Q2
$27.3M Sell
369,734
-453,260
-55% -$34.1M 0.02% 660
2020
Q1
$60.4M Sell
822,994
-324,880
-28% -$25.5M 0.05% 303
2019
Q4
$99.6M Buy
1,147,874
+156,256
+16% +$12.8M 0.07% 257
2019
Q3
$79.7M Sell
991,618
-119,472
-11% -$9.57M 0.06% 298
2019
Q2
$88.9M Buy
1,111,090
+223,853
+25% +$17.1M 0.07% 260
2019
Q1
$70.4M Sell
887,237
-139,384
-14% -$10.4M 0.07% 272
2018
Q4
$74.9M Buy
1,026,621
+445,400
+77% +$31.4M 0.08% 259
2018
Q3
$39.3M Sell
581,221
-102,704
-15% -$6.54M 0.04% 501
2018
Q2
$39.6M Buy
683,925
+2,935
+0.4% +$166K 0.04% 449
2018
Q1
$35.4M Sell
680,990
-291,240
-30% -$15.7M 0.03% 519
2017
Q4
$52.2M Buy
972,230
+466,151
+92% +$25.8M 0.04% 419
2017
Q3
$30.9M Sell
506,079
-206,875
-29% -$12.5M 0.03% 593
2017
Q2
$43.6M Sell
712,954
-147,454
-17% -$8.98M 0.04% 407
2017
Q1
$52.2M Sell
860,408
-833,370
-49% -$50.6M 0.05% 345
2016
Q4
$95.1M Sell
1,693,778
-48,417
-3% -$2.83M 0.09% 213
2016
Q3
$104M Buy
1,742,195
+24,733
+1% +$1.45M 0.1% 180
2016
Q2
$94.4M Sell
1,717,462
-16,664
-1% -$887K 0.1% 190
2016
Q1
$87.6M Buy
1,734,126
+851,500
+96% +$41.7M 0.1% 187
2015
Q4
$44.5M Buy
882,626
+34,689
+4% +$1.75M 0.04% 399
2015
Q3
$40M Sell
847,937
-126,598
-13% -$6.73M 0.04% 412
2015
Q2
$52.9M Buy
974,535
+473,172
+94% +$26.5M 0.05% 376
2015
Q1
$27.5M Sell
501,363
-442,047
-47% -$25M 0.03% 607
2014
Q4
$51.1M Buy
943,410
+163,593
+21% +$9.11M 0.05% 395
2014
Q3
$44.1M Buy
779,817
+1,782
+0.2% +$100K 0.04% 440
2014
Q2
$42.9M Buy
778,035
+165,689
+27% +$9.04M 0.04% 412
2014
Q1
$33.2M Sell
612,346
-195,662
-24% -$10.1M 0.03% 478
2013
Q4
$38.6M Sell
808,008
-143,890
-15% -$6.58M 0.03% 470
2013
Q3
$43.2M Sell
951,898
-183,296
-16% -$8.37M 0.04% 398
2013
Q2
$50.3M Buy
+1,135,194
New +$50.7M 0.05% 310

Other funds holding MRK

Citigroup's MRK Position: Q1 2026 in Review

Citigroup increased its Merck (MRK) stake by 5.4% in Q1 2026, buying an estimated $16.5M and bringing the position to 2,779,106 shares worth $334M. The position accounts for 0.14% of the portfolio, ranked #137.

Citigroup first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $824M in Q2 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Citigroup held 2,779,106 shares of Merck worth $334M as of Q1 2026.
  • Citigroup bought 142,995 Merck shares in Q1 2026, an estimated $16.5M.
  • Merck made up 0.14% of Citigroup's portfolio in Q1 2026, its #137 holding.
  • Citigroup first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Merck position peaked at $824M in Q2 2024.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.